Breast Cancer Liquid Biopsy Market Seen Reaching $1.75 Billion by 2030

The breast cancer liquid biopsy market is projected to grow from $0.89 billion in 2025 to $1.75 billion by 2030, driven by rising breast cancer cases, precision oncology adoption and non-invasive monitoring tools. North America led the market in 2025, while Asia-Pacific is expected to grow fastest.

Why it matters: - Breast cancer liquid biopsy is becoming a more important tool for detecting tumor-derived signals in blood without relying on conventional tissue biopsy. - The market’s projected growth reflects rising demand for faster diagnosis, real-time monitoring and treatment guidance in breast cancer care. - The trend matters for patients, labs and oncology providers as liquid biopsy moves deeper into routine cancer management.

What happened: - The Business Research Company released a report on the global breast cancer liquid biopsy market. - The market is expected to rise from $0.89 billion in 2025 to $1.02 billion in 2026. - The report projects the market will reach $1.75 billion by 2030. - The report puts 2025-2026 growth at a 14.6% compound annual growth rate and 2026-2030 growth at 14.3%. - North America held the largest market share in 2025. - Asia-Pacific is forecast to be the fastest-growing region in the coming years. - A free sample of the report is available. - The full report is also available.

The details: - Breast cancer liquid biopsy is a minimally invasive diagnostic test that analyzes tumor-derived substances in blood or other bodily fluids. - The test can provide information on the presence, progression and genetic characteristics of breast cancer. - The market’s growth has been supported by rising breast cancer prevalence, limitations of traditional tissue biopsy, advances in oncology diagnostics, expanded cancer screening awareness and growth in laboratory testing services. - The report identifies precision oncology, AI-based mutation analysis, personalized treatment planning, circulating free DNA testing and decentralized cancer diagnostics as key growth drivers ahead. - Emerging trends include multi-biomarker blood-based testing, non-invasive cancer monitoring, treatment-response tracking, early recurrence detection and tailored oncology diagnostics. - Liquid biopsy can detect circulating tumor DNA and circulating tumor cells in the bloodstream. - That capability supports real-time disease monitoring, treatment-effectiveness checks, therapy-resistance detection and mutation analysis for targeted therapy selection. - The American Cancer Society projects 319,750 new breast cancer diagnoses in the US in 2025, up from 313,510 in 2024. - The report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - The 2026 edition adds market attractiveness scoring, total addressable market analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspot infographics and updated graphics.

Between the lines: - The report signals that liquid biopsy is moving from a niche diagnostic approach toward a broader role in cancer monitoring and treatment planning. - The strong growth forecast suggests rising adoption even as traditional tissue biopsy remains a key standard in oncology. - The focus on AI, cfDNA and decentralized diagnostics points to a market shifting toward more distributed and data-driven testing workflows.

What's next: - Continued growth is expected as precision oncology expands and more health systems adopt non-invasive monitoring tools. - Faster growth in Asia-Pacific suggests the region may become a bigger commercial focus for diagnostic companies and testing providers. - The report’s forecasting tools and regional analysis may help vendors and investors identify the most active opportunities in the sector.